OVCON-35 Drug Patent Profile
When do Ovcon-35 patents expire, and what generic alternatives are available?
Ovcon-35 is a drug marketed by Warner Chilcott and Warner Chilcott Llc and is included in two NDAs.
The generic ingredient in OVCON-35 is ethinyl estradiol; norethindrone. Fifteen suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; norethindrone profile page.
US Patents and Regulatory Information for OVCON-35
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Warner Chilcott | OVCON-35 | ethinyl estradiol; norethindrone | TABLET;ORAL-21 | 018127-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Warner Chilcott Llc | OVCON-35 | ethinyl estradiol; norethindrone | TABLET;ORAL-28 | 017716-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
